Ilex/Millennium Campath
Executive Summary
FDA's Oncologic Drugs Advisory Committee will review alemtuzumab on Dec. 14 for the treatment of patients with chronic lymphocytic leukemia who have been treated with alkylating agents and have failed fludarabine therapy. The meeting will begin at 8 a.m. at the Holiday Inn-Bethesda, Md. In the afternoon, the committee will discuss single patient exemptions for the use of unapproved oncologic drugs and biologics